期刊
DERMATOLOGIC THERAPY
卷 34, 期 5, 页码 -出版社
WILEY-HINDAWI
DOI: 10.1111/dth.15035
关键词
adolescents; atopic dermatitis; COVID-19; dupilumab; real-world
类别
This study reported the real-world effectiveness and safety of dupilumab in adolescents with moderate to severe AD during the COVID-19 pandemic in Italy from January to October 2020. The results showed excellent effectiveness of dupilumab with higher improvement than observed in clinical trials, and a good safety profile was maintained throughout the treatment period, despite one patient contracting asymptomatic SARS-CoV-2 infection and another developing mild conjunctivitis.
Dupilumab showed significant improvement of adolescent atopic dermatitis (AD) signs and symptoms in clinical trials, with a good safety profile. Herein we report the real-word effectiveness and safety of dupilumab in adolescents with moderate to severe AD from January to October 2020, during the COVID-19 pandemic in Italy. All patients had a diagnosis of AD for a mean [SD] 12.8 [3.1] years. Baseline demographics, AD characteristics (EASI, cDLQI, NRS itch score, NRS sleep loss score) at baseline and week 16, and safety data were collected. Nineteen patients (52.6% men; mean [SD] age, 15.6 [1.4] years [range, 13-17 years]) were included in the analysis. All patients reached EASI-50 and 78.9% EASI-75, especially in those with EASI >= 30 and BMI < 25 at baseline, with marked reduction for cDLQI (77.4%), NRS itch score (5.9 point), and NRS sleep loss score (87.5%). One patient contracted asymptomatic SARS-CoV-2 infection and 1 developed mild conjuntivitis, without stopping dupilumab. In this real-word experience the effectiveness of dupilumab was excellent and resulted higher than that observed in clinical trials, with a good safety profile during COVID-19 pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据